organization · Reporting owner
Caissa Capital Management ltd.
Disclosed activity across 1 company
Sign in to followReported relationships
Latest disclosed role at each company.
No relationships currently tracked through insider filings.
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
No balances currently tracked through insider filings.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Avalo Therapeutics, Inc.
Report date June 26, 2023 · Filed June 27, 2023
Section 16 reporting ended · disclosed 2023-06-27. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee Footnote (1) | 0 |
Reported balance
After 2023-06-26 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2023-06-26 · Purchase · Disposed 1,425,700 · Balance 0 F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.45 to $0.84, inclusive. F1: Shares held by Caissa Capital Management Ltd, a British Virgin Islands company controlled by Mr. Golestaneh. |
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2023-06-26 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2023-06-26 · Purchase · Disposed 182,300 · Balance 0 F3: These shares are directly owned by Mr. Golestaneh in his personal capacity. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares held by Caissa Capital Management Ltd, a British Virgin Islands company controlled by Mr. Golestaneh.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.45 to $0.84, inclusive.
F3: These shares are directly owned by Mr. Golestaneh in his personal capacity.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 26, 2023 Filed Jun 27, 2023 16:10 UTC | Avalo Therapeutics, Inc. AVTX · Entity 4936 | PurchaseCommon Stock | 182,300 | $0.62 | $113,026.00 |
DisclosureSEC source: 0001929354-23-000016 · primary_doc.xml · nonDerivative · entry 2 Caissa Capital Management ltd. · CIK 0001929354 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F3 · ownership.direct: These shares are directly owned by Mr. Golestaneh in his personal capacity. Read SEC document |
| June 26, 2023 Filed Jun 27, 2023 16:10 UTC | Avalo Therapeutics, Inc. AVTX · Entity 4936 | PurchaseCommon Stock | 1,425,700 | $0.64 | $917,152.81 |
DisclosureSEC source: 0001929354-23-000016 · primary_doc.xml · nonDerivative · entry 1 Caissa Capital Management ltd. · CIK 0001929354 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote (1) Disclosed balance after: 0 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.45 to $0.84, inclusive. F1 · ownership.nature: Shares held by Caissa Capital Management Ltd, a British Virgin Islands company controlled by Mr. Golestaneh. Read SEC document |
| June 20, 2023 Filed Jun 20, 2023 16:04 UTC | Avalo Therapeutics, Inc. AVTX · Entity 4936 | PurchaseCommon Stock | 2,000 | $4.14 | $8,288.80 |
DisclosureSEC source: 0001929354-23-000015 · primary_doc.xml · nonDerivative · entry 3 Caissa Capital Management ltd. · CIK 0001929354 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote (1) Disclosed balance after: 1,425,700 F4 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.07 to $4.17, inclusive. F1 · ownership.nature: Shares held by Caissa Capital Management Ltd, a British Virgin Islands company controlled by Mr. Golestaneh. Read SEC document |
| June 16, 2023 Filed Jun 20, 2023 16:04 UTC | Avalo Therapeutics, Inc. AVTX · Entity 4936 | PurchaseCommon Stock | 3,000 | $3.90 | $11,714.40 |
DisclosureSEC source: 0001929354-23-000015 · primary_doc.xml · nonDerivative · entry 2 Caissa Capital Management ltd. · CIK 0001929354 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote (1) Disclosed balance after: 1,423,700 F3 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.745 to $3.98, inclusive. F1 · ownership.nature: Shares held by Caissa Capital Management Ltd, a British Virgin Islands company controlled by Mr. Golestaneh. Read SEC document |
| June 15, 2023 Filed Jun 20, 2023 16:04 UTC | Avalo Therapeutics, Inc. AVTX · Entity 4936 | PurchaseCommon Stock | 3,160 | $3.68 | $11,640.49 |
DisclosureSEC source: 0001929354-23-000015 · primary_doc.xml · nonDerivative · entry 1 Caissa Capital Management ltd. · CIK 0001929354 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote (1) Disclosed balance after: 1,420,700 F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.19 to $3.99, inclusive. F1 · ownership.nature: Shares held by Caissa Capital Management Ltd, a British Virgin Islands company controlled by Mr. Golestaneh. Read SEC document |
| June 14, 2023 Filed Jun 14, 2023 16:14 UTC | Avalo Therapeutics, Inc. AVTX · Entity 4936 | PurchaseCommon Stock | 6,000 | $3.48 | $20,874.00 |
DisclosureSEC source: 0001929354-23-000014 · primary_doc.xml · nonDerivative · entry 3 Caissa Capital Management ltd. · CIK 0001929354 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote (1) Disclosed balance after: 1,417,540 F4 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.245 to $3.55, inclusive. F1 · ownership.nature: Shares held by Caissa Capital Management Ltd, a British Virgin Islands company controlled by Mr. Golestaneh. Read SEC document |
| June 13, 2023 Filed Jun 14, 2023 16:14 UTC | Avalo Therapeutics, Inc. AVTX · Entity 4936 | PurchaseCommon Stock | 8,750 | $3.82 | $33,439.00 |
DisclosureSEC source: 0001929354-23-000014 · primary_doc.xml · nonDerivative · entry 2 Caissa Capital Management ltd. · CIK 0001929354 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote (1) Disclosed balance after: 1,411,540 F3 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.7 to $3.83, inclusive. F1 · ownership.nature: Shares held by Caissa Capital Management Ltd, a British Virgin Islands company controlled by Mr. Golestaneh. Read SEC document |
| June 12, 2023 Filed Jun 14, 2023 16:14 UTC | Avalo Therapeutics, Inc. AVTX · Entity 4936 | PurchaseCommon Stock | 2,149 | $4.34 | $9,316.34 |
DisclosureSEC source: 0001929354-23-000014 · primary_doc.xml · nonDerivative · entry 1 Caissa Capital Management ltd. · CIK 0001929354 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote (1) Disclosed balance after: 1,402,790 F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.125 to $4.47, inclusive. F1 · ownership.nature: Shares held by Caissa Capital Management Ltd, a British Virgin Islands company controlled by Mr. Golestaneh. Read SEC document |
| June 09, 2023 Filed Jun 9, 2023 16:24 UTC | Avalo Therapeutics, Inc. AVTX · Entity 4936 | PurchaseCommon Stock | 5,044 | $4.14 | $20,895.78 |
DisclosureSEC source: 0001929354-23-000013 · primary_doc.xml · nonDerivative · entry 3 Caissa Capital Management ltd. · CIK 0001929354 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote (1) Disclosed balance after: 1,400,641 F4 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.01 to $4.3, inclusive. F1 · ownership.nature: Shares held by Caissa Capital Management Ltd, a British Virgin Islands company controlled by Mr. Golestaneh. Read SEC document |
| June 08, 2023 Filed Jun 9, 2023 16:24 UTC | Avalo Therapeutics, Inc. AVTX · Entity 4936 | PurchaseCommon Stock | 6,398 | $3.93 | $25,125.59 |
DisclosureSEC source: 0001929354-23-000013 · primary_doc.xml · nonDerivative · entry 2 Caissa Capital Management ltd. · CIK 0001929354 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote (1) Disclosed balance after: 1,395,597 F3 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.775 to $4.22, inclusive. F1 · ownership.nature: Shares held by Caissa Capital Management Ltd, a British Virgin Islands company controlled by Mr. Golestaneh. Read SEC document |
| June 07, 2023 Filed Jun 9, 2023 16:24 UTC | Avalo Therapeutics, Inc. AVTX · Entity 4936 | PurchaseCommon Stock | 2,984 | $3.49 | $10,418.34 |
DisclosureSEC source: 0001929354-23-000013 · primary_doc.xml · nonDerivative · entry 1 Caissa Capital Management ltd. · CIK 0001929354 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote (1) Disclosed balance after: 1,389,199 F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.90 to $3.6, inclusive. F1 · ownership.nature: Shares held by Caissa Capital Management Ltd, a British Virgin Islands company controlled by Mr. Golestaneh. Read SEC document |
| May 31, 2023 Filed Jun 2, 2023 16:22 UTC | Avalo Therapeutics, Inc. AVTX · Entity 4936 | PurchaseCommon Stock | 844 | $2.87 | $2,422.28 |
DisclosureSEC source: 0001929354-23-000012 · primary_doc.xml · nonDerivative · entry 1 Caissa Capital Management ltd. · CIK 0001929354 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote (1) Disclosed balance after: 1,386,215 F1 · ownership.nature: Shares held by Caissa Capital Management Ltd, a British Virgin Islands company controlled by Mr. Golestaneh. Read SEC document |
| May 30, 2023 Filed May 30, 2023 16:27 UTC | Avalo Therapeutics, Inc. AVTX · Entity 4936 | PurchaseCommon stock | 671 | $2.87 | $1,923.76 |
DisclosureSEC source: 0001929354-23-000011 · primary_doc.xml · nonDerivative · entry 2 Caissa Capital Management ltd. · CIK 0001929354 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote (1) Disclosed balance after: 1,385,371 F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.85 to $2.87, inclusive. F1 · ownership.nature: Shares held by Caissa Capital Management Ltd, a British Virgin Islands company controlled by Mr. Golestaneh. Read SEC document |
| May 25, 2023 Filed May 30, 2023 16:27 UTC | Avalo Therapeutics, Inc. AVTX · Entity 4936 | PurchaseCommon stock | 2,000 | $2.77 | $5,540.00 |
DisclosureSEC source: 0001929354-23-000011 · primary_doc.xml · nonDerivative · entry 1 Caissa Capital Management ltd. · CIK 0001929354 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote (1) Disclosed balance after: 1,384,700 F1 · ownership.nature: Shares held by Caissa Capital Management Ltd, a British Virgin Islands company controlled by Mr. Golestaneh. Read SEC document |
| May 24, 2023 Filed May 24, 2023 16:15 UTC | Avalo Therapeutics, Inc. AVTX · Entity 4936 | PurchaseCommon Stock | 5,519 | $2.96 | $16,348.38 |
DisclosureSEC source: 0001929354-23-000010 · primary_doc.xml · nonDerivative · entry 2 Caissa Capital Management ltd. · CIK 0001929354 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote (1) Disclosed balance after: 1,382,700 F3 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.92 to $3.03, inclusive. F1 · ownership.nature: Shares held by Caissa Capital Management Ltd, a British Virgin Islands company controlled by Mr. Golestaneh. Read SEC document |
| May 24, 2023 Filed May 24, 2023 16:15 UTC | Avalo Therapeutics, Inc. AVTX · Entity 4936 | PurchaseCommon Stock | 3,481 | $3.01 | $10,468.06 |
DisclosureSEC source: 0001929354-23-000010 · primary_doc.xml · nonDerivative · entry 1 Caissa Capital Management ltd. · CIK 0001929354 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote (1) Disclosed balance after: 1,377,181 F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.0 to $3.01, inclusive. F1 · ownership.nature: Shares held by Caissa Capital Management Ltd, a British Virgin Islands company controlled by Mr. Golestaneh. Read SEC document |
| May 22, 2023 Filed May 22, 2023 16:30 UTC | Avalo Therapeutics, Inc. AVTX · Entity 4936 | PurchaseCommon stock | 7,000 | $3.34 | $23,357.60 |
DisclosureSEC source: 0001929354-23-000009 · primary_doc.xml · nonDerivative · entry 3 Caissa Capital Management ltd. · CIK 0001929354 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote (1) Disclosed balance after: 1,373,700 F4 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.00 to $3.72, inclusive. F1 · ownership.nature: Shares held by Caissa Capital Management Ltd, a British Virgin Islands company controlled by Mr. Golestaneh. Read SEC document |
| May 19, 2023 Filed May 22, 2023 16:30 UTC | Avalo Therapeutics, Inc. AVTX · Entity 4936 | PurchaseCommon stock | 6,500 | $3.52 | $22,852.05 |
DisclosureSEC source: 0001929354-23-000009 · primary_doc.xml · nonDerivative · entry 2 Caissa Capital Management ltd. · CIK 0001929354 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote (1) Disclosed balance after: 1,366,700 F3 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.4 to $3.6, inclusive. F1 · ownership.nature: Shares held by Caissa Capital Management Ltd, a British Virgin Islands company controlled by Mr. Golestaneh. Read SEC document |
| May 18, 2023 Filed May 22, 2023 16:30 UTC | Avalo Therapeutics, Inc. AVTX · Entity 4936 | PurchaseCommon stock | 13,121 | $3.29 | $43,162.84 |
DisclosureSEC source: 0001929354-23-000009 · primary_doc.xml · nonDerivative · entry 1 Caissa Capital Management ltd. · CIK 0001929354 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote (1) Disclosed balance after: 1,360,200 F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.80 to $3.40, inclusive. F1 · ownership.nature: Shares held by Caissa Capital Management Ltd, a British Virgin Islands company controlled by Mr. Golestaneh. Read SEC document |
| May 16, 2023 Filed May 16, 2023 17:23 UTC | Avalo Therapeutics, Inc. AVTX · Entity 4936 | PurchaseCommon stock | 379 | $2.75 | $1,042.25 |
DisclosureSEC source: 0001929354-23-000008 · primary_doc.xml · nonDerivative · entry 3 Caissa Capital Management ltd. · CIK 0001929354 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote (1) Disclosed balance after: 1,347,079 F1 · ownership.nature: Shares held by Caissa Capital Management Ltd, a British Virgin Islands company controlled by Mr. Golestaneh. Read SEC document |
| May 15, 2023 Filed May 16, 2023 17:23 UTC | Avalo Therapeutics, Inc. AVTX · Entity 4936 | PurchaseCommon stock | 1,715 | $2.55 | $4,366.22 |
DisclosureSEC source: 0001929354-23-000008 · primary_doc.xml · nonDerivative · entry 2 Caissa Capital Management ltd. · CIK 0001929354 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote (1) Disclosed balance after: 1,346,700 F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.45 to $2.79, inclusive. F1 · ownership.nature: Shares held by Caissa Capital Management Ltd, a British Virgin Islands company controlled by Mr. Golestaneh. Read SEC document |
| May 12, 2023 Filed May 16, 2023 17:23 UTC | Avalo Therapeutics, Inc. AVTX · Entity 4936 | PurchaseCommon stock | 2,285 | $2.45 | $5,598.25 |
DisclosureSEC source: 0001929354-23-000008 · primary_doc.xml · nonDerivative · entry 1 Caissa Capital Management ltd. · CIK 0001929354 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote (1) Disclosed balance after: 1,344,985 F1 · ownership.nature: Shares held by Caissa Capital Management Ltd, a British Virgin Islands company controlled by Mr. Golestaneh. Read SEC document |
| May 08, 2023 Filed May 8, 2023 16:10 UTC | Avalo Therapeutics, Inc. AVTX · Entity 4936 | PurchaseCommon Stock | 5,000 | $2.62 | $13,108.00 |
DisclosureSEC source: 0001929354-23-000007 · primary_doc.xml · nonDerivative · entry 3 Caissa Capital Management ltd. · CIK 0001929354 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote (1) Disclosed balance after: 1,342,700 F4 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.575 to $2.68, inclusive. F1 · ownership.nature: Shares held by Caissa Capital Management Ltd, a British Virgin Islands company controlled by Mr. Golestaneh. Read SEC document |
| May 05, 2023 Filed May 8, 2023 16:10 UTC | Avalo Therapeutics, Inc. AVTX · Entity 4936 | PurchaseCommon Stock | 5,000 | $2.88 | $14,375.00 |
DisclosureSEC source: 0001929354-23-000007 · primary_doc.xml · nonDerivative · entry 2 Caissa Capital Management ltd. · CIK 0001929354 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote (1) Disclosed balance after: 1,337,700 F3 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.85 to $2.9, inclusive. F1 · ownership.nature: Shares held by Caissa Capital Management Ltd, a British Virgin Islands company controlled by Mr. Golestaneh. Read SEC document |
| May 04, 2023 Filed May 8, 2023 16:10 UTC | Avalo Therapeutics, Inc. AVTX · Entity 4936 | PurchaseCommon Stock | 15,000 | $2.79 | $41,881.50 |
DisclosureSEC source: 0001929354-23-000007 · primary_doc.xml · nonDerivative · entry 1 Caissa Capital Management ltd. · CIK 0001929354 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote (1) Disclosed balance after: 1,332,700 F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.58 to $2.85, inclusive. F1 · ownership.nature: Shares held by Caissa Capital Management Ltd, a British Virgin Islands company controlled by Mr. Golestaneh. Read SEC document |
| April 27, 2023 Filed Apr 27, 2023 16:07 UTC | Avalo Therapeutics, Inc. AVTX · Entity 4936 | PurchaseCommon Stock | 1,504 | $2.96 | $4,451.84 |
DisclosureSEC source: 0001929354-23-000006 · primary_doc.xml · nonDerivative · entry 3 Caissa Capital Management ltd. · CIK 0001929354 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote (1) Disclosed balance after: 1,317,700 F3 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.95 to $2.97, inclusive. F1 · ownership.nature: Shares held by Caissa Capital Management Ltd, a British Virgin Islands company controlled by Mr. Golestaneh. Read SEC document |
| April 26, 2023 Filed Apr 27, 2023 16:07 UTC | Avalo Therapeutics, Inc. AVTX · Entity 4936 | PurchaseCommon Stock | 425 | $2.97 | $1,262.25 |
DisclosureSEC source: 0001929354-23-000006 · primary_doc.xml · nonDerivative · entry 2 Caissa Capital Management ltd. · CIK 0001929354 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote (1) Disclosed balance after: 1,316,196 F1 · ownership.nature: Shares held by Caissa Capital Management Ltd, a British Virgin Islands company controlled by Mr. Golestaneh. Read SEC document |
| April 25, 2023 Filed Apr 27, 2023 16:07 UTC | Avalo Therapeutics, Inc. AVTX · Entity 4936 | PurchaseCommon Stock | 5,571 | $3.00 | $16,709.10 |
DisclosureSEC source: 0001929354-23-000006 · primary_doc.xml · nonDerivative · entry 1 Caissa Capital Management ltd. · CIK 0001929354 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote (1) Disclosed balance after: 1,315,771 F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.97 to $3.05, inclusive. F1 · ownership.nature: Shares held by Caissa Capital Management Ltd, a British Virgin Islands company controlled by Mr. Golestaneh. Read SEC document |
| April 24, 2023 Filed Apr 24, 2023 16:32 UTC | Avalo Therapeutics, Inc. AVTX · Entity 4936 | PurchaseCommon Stock | 12,500 | $3.06 | $38,280.00 |
DisclosureSEC source: 0001929354-23-000005 · primary_doc.xml · nonDerivative · entry 2 Caissa Capital Management ltd. · CIK 0001929354 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote (1) Disclosed balance after: 1,310,200 F3 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.94 to $3.15, inclusive. F1 · ownership.nature: Shares held by Caissa Capital Management Ltd, a British Virgin Islands company controlled by Mr. Golestaneh. Read SEC document |
| April 20, 2023 Filed Apr 24, 2023 16:32 UTC | Avalo Therapeutics, Inc. AVTX · Entity 4936 | PurchaseCommon Stock | 5,000 | $3.08 | $15,391.50 |
DisclosureSEC source: 0001929354-23-000005 · primary_doc.xml · nonDerivative · entry 1 Caissa Capital Management ltd. · CIK 0001929354 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote (1) Disclosed balance after: 1,297,700 F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.94 to $3.14, inclusive. F1 · ownership.nature: Shares held by Caissa Capital Management Ltd, a British Virgin Islands company controlled by Mr. Golestaneh. Read SEC document |
| April 18, 2023 Filed Apr 18, 2023 16:08 UTC | Avalo Therapeutics, Inc. AVTX · Entity 4936 | PurchaseCommon Stock | 10,000 | $2.94 | $29,438.00 |
DisclosureSEC source: 0001929354-23-000003 · primary_doc.xml · nonDerivative · entry 2 Caissa Capital Management ltd. · CIK 0001929354 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote (1) Disclosed balance after: 1,292,700 F3 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.82 to $3.01, inclusive. F1 · ownership.nature: Shares held by Caissa Capital Management Ltd, a British Virgin Islands company controlled by Mr. Golestaneh Read SEC document |
| April 17, 2023 Filed Apr 18, 2023 16:08 UTC | Avalo Therapeutics, Inc. AVTX · Entity 4936 | PurchaseCommon Stock | 15,000 | $2.96 | $44,436.00 |
DisclosureSEC source: 0001929354-23-000003 · primary_doc.xml · nonDerivative · entry 1 Caissa Capital Management ltd. · CIK 0001929354 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote (1) Disclosed balance after: 1,282,700 F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.60 to $3.09, inclusive. F1 · ownership.nature: Shares held by Caissa Capital Management Ltd, a British Virgin Islands company controlled by Mr. Golestaneh Read SEC document |
| April 11, 2023 Filed Apr 11, 2023 16:51 UTC | Avalo Therapeutics, Inc. AVTX · Entity 4936 | PurchaseCommon Stock | 25,000 | $2.84 | $71,080.00 |
DisclosureSEC source: 0001929354-23-000002 · primary_doc.xml · nonDerivative · entry 2 Caissa Capital Management ltd. · CIK 0001929354 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote (1) Disclosed balance after: 1,267,700 F3 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.41 to $3.225, inclusive. F1 · ownership.nature: Shares held by Caissa Capital Management Ltd, a British Virgin Islands company controlled by Mr. Golestaneh Read SEC document |
| April 10, 2023 Filed Apr 11, 2023 16:51 UTC | Avalo Therapeutics, Inc. AVTX · Entity 4936 | PurchaseCommon Stock | 31,329 | $2.28 | $71,436.39 |
DisclosureSEC source: 0001929354-23-000002 · primary_doc.xml · nonDerivative · entry 1 Caissa Capital Management ltd. · CIK 0001929354 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote (1) Disclosed balance after: 1,242,700 F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.835 to $2.51, inclusive. F1 · ownership.nature: Shares held by Caissa Capital Management Ltd, a British Virgin Islands company controlled by Mr. Golestaneh Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.